Eczema drug Tralokinumab's eye risks under the microscope
NCT ID NCT05682976
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 100 adults with atopic dermatitis (eczema) who were prescribed tralokinumab. Researchers tracked how many developed eye problems like conjunctivitis within 4 months of starting the drug. The goal was to better understand these side effects in real-world use, not to test if the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tralokinumab
What this could lead to
If successful, this study could help doctors better understand and manage eye side effects of tralokinumab, improving treatment safety for eczema patients.
What could go wrong
This is a small, completed observational study (100 participants) that only tracks side effects, not treatment effectiveness. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Lille
Lille, France
-
CHU de Bordeaux
Bordeaux, France
-
CHU de Brest
Brest, France
-
CHU de Clermont Ferrand
Clermont-Ferrand, France
-
CHU de Nantes
Nantes, France
-
CHU de Rouen
Rouen, France
-
CHu de Dijon
Dijon, France
-
CHu de Poitiers
Poitiers, France
-
CHu de Rennes
Rennes, France
-
Hospice Civil de Lyon
Lyon, France
-
Hôpital Saint Louis
Paris, France